These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 12928471)

  • 1. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence.
    Hackam DG; Anand SS
    JAMA; 2003 Aug; 290(7):932-40. PubMed ID: 12928471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease.
    Ridker PM; Stampfer MJ; Rifai N
    JAMA; 2001 May; 285(19):2481-5. PubMed ID: 11368701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Homocysteine--CRP--lipoprotein (a). When do you evaluate the "new" risk factors].
    Parhofer KG
    MMW Fortschr Med; 2001 Jan; 143(4):22-4. PubMed ID: 11219276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel risk factors for atherosclerosis.
    Kullo IJ; Gau GT; Tajik AJ
    Mayo Clin Proc; 2000 Apr; 75(4):369-80. PubMed ID: 10761492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conditional risk factors for atherosclerosis.
    Kullo IJ; Ballantyne CM
    Mayo Clin Proc; 2005 Feb; 80(2):219-30. PubMed ID: 15704777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study.
    Sarafidis PA; Lasaridis AN; Nilsson PM; Mouslech TF; Hitoglou-Makedou AD; Stafylas PC; Kazakos KA; Yovos JG; Tourkantonis AA
    Metabolism; 2005 Sep; 54(9):1236-42. PubMed ID: 16125536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Novel risk factors for atherosclerosis. A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a) and cholesterol as predictors of peripheral arteriopathy].
    Iacoviello L; Donati MB; de Gaetano G
    Ital Heart J Suppl; 2001 Sep; 2(9):1031-3. PubMed ID: 11675827
    [No Abstract]   [Full Text] [Related]  

  • 8. [Less common risk factors for atherogenesis--homocysteine, lipoprotein (a) and C-reactive protein].
    Racek J; Racková M
    Cas Lek Cesk; 2002 Sep; 141(19):605-9. PubMed ID: 12501503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atherosclerotic renal artery stenosis: association with emerging vascular risk factors.
    Paraskevas KI; Hamilton G; Cross JM; Mikhailidis DP
    Nephron Clin Pract; 2008; 108(1):c56-66. PubMed ID: 18097149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging risk factors for cardiovascular disease: a review of the epidemiologic evidence for lipoprotein(a), homocysteine, and fibrinogen.
    Catena C; Cavarape A; Dotto L; Colussi G; Novehllo M; De Marchi S; Sechi LA
    Adv Clin Path; 2003 Jan; 7(1):3-11. PubMed ID: 19774732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-traditional risk factors for atherosclerosis.
    Acevedo M; Tagle R; Simpfendorfer C
    Rev Med Chil; 2001 Oct; 129(10):1212-21. PubMed ID: 11775351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of homocysteine, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen and advanced glycation end-products) for atherogenesis in uraemic patients.
    Massy ZA
    Nephrol Dial Transplant; 2000; 15 Suppl 5():81-91. PubMed ID: 11073279
    [No Abstract]   [Full Text] [Related]  

  • 13. Homocysteine and other cardiovascular risk factors in patients with lichen planus.
    Saleh N; Samir N; Megahed H; Farid E
    J Eur Acad Dermatol Venereol; 2014 Nov; 28(11):1507-13. PubMed ID: 24330130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homocysteine, fibrinogen, and lipoprotein(a) levels are simultaneously reduced in patients with chronic renal failure treated with folic acid, pyridoxine, and cyanocobalamin.
    Naruszewicz M; Klinke M; Dziewanowski K; Staniewicz A; Bukowska H
    Metabolism; 2001 Feb; 50(2):131-4. PubMed ID: 11229418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homocysteine and occlusive arterial disease.
    O'Grady H; Kelly C; Bouchier-Hayes D; Leahy A
    Br J Surg; 2002 Jul; 89(7):838-44. PubMed ID: 12081732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. History of emerging vascular disease risk factors.
    Pilgeram L
    JAMA; 2004 Nov; 292(17):2086; author reply 2086. PubMed ID: 15523068
    [No Abstract]   [Full Text] [Related]  

  • 17. Homocysteine, lipoprotein(a) and fibrinogen: metabolic risk factors for cardiovascular complications of chronic renal disease.
    Kronenberg F
    Curr Opin Nephrol Hypertens; 1998 May; 7(3):271-8. PubMed ID: 9617557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease.
    Eikelboom JW; Hankey GJ
    Curr Opin Nephrol Hypertens; 2001 May; 10(3):377-83. PubMed ID: 11342801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study.
    Zakai NA; Katz R; Jenny NS; Psaty BM; Reiner AP; Schwartz SM; Cushman M
    J Thromb Haemost; 2007 Jun; 5(6):1128-35. PubMed ID: 17388967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study.
    Alfthan G; Pekkanen J; Jauhiainen M; Pitkäniemi J; Karvonen M; Tuomilehto J; Salonen JT; Ehnholm C
    Atherosclerosis; 1994 Mar; 106(1):9-19. PubMed ID: 8018111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.